News/Events/Diabeloop Heads to ATTD 2026: Exploring Physical Activity and Gender Dynamics in AID Systems

Diabeloop Heads to ATTD 2026: Exploring Physical Activity and Gender Dynamics in AID Systems

Date

Share

Facebook Twitter Linkedin

We are excited to announce that Diabeloop will be participating in the upcoming Advanced Technologies & Treatments for Diabetes (ATTD) 2026 conference next week. Our team will be presenting compelling new data focused on one of the most persistent challenges in type 1 diabetes management: physical activity.

At Diabeloop, we are constantly analyzing real-world data to refine our algorithms and improve the daily lives of people living with diabetes. This year at ATTD, our research highlights how our DBLG AID system responds to exercise, with a specific focus on the timing of activity declarations and the impact of gender dynamics.

We invite all attendees, healthcare professionals, and industry partners to join us for our sessions:

🎤 Short Oral Presentation: A Gender-Based Analysis

Personalized care means understanding that diabetes affects everyone differently. Our  presentation delves into the intersection of gender and physical activity management, showcasing how these variables interact within the DBLG1 ecosystem.

  • Abstract #320: GENDER ANALYSIS OF PHYSICAL ACTIVITY MANAGEMENT IN DBLG1 SYSTEM
  • Session: Short Oral Session 09: INSULIN PUMPS
  • Date: Friday, 13 March 2026
  • Time: 10:35 – 11:00

🖼️ Poster Viewing: The Impact of Timing on Exercise

Managing physical activity with an Automated Insulin Delivery (AID) system requires precision. Our poster explores how the specific timing of when a patient declares their physical activity impacts overall glycemic outcomes.

  • Abstract #318: IMPACT OF PHYSICAL ACTIVITY DECLARATION TIMING ON GLYCEMIC OUTCOMES IN DBLG1 SYSTEMS
  • Location: Poster Viewing Area

Connect with the Diabeloop Team

Conferences like ATTD are vital for the exchange of ideas that push MedTech forward. If you are attending ATTD 2026, we would love to connect. Reach out to our team on-site to discuss our latest clinical findings, explore the DBLG1 system, and talk about the future of Automated Insulin Delivery technology.

We recommend you